

1 **Importance of human milk for health and as antiviral**  
2 **immunotherapy - a narrative review**

3  
4 **ABSTRACT**

**Background** Immunological protection against novel mucosal pathogens is crucial to us as our immunity is unable to effectively defend against specific pathogens without previous immune encounter, as experienced in the SARS-CoV-2 pandemic. However, a nursing neonate is protected from many novel infections by exclusive human milk feeding despite having a naïve immune system without much previous pathogen exposure. It is observed that SARS-CoV-2 is not transmitted to the nursing infant through human milk, and that natural maternal infections produce specific antibody responses in human milk. Furthermore, maternal vaccination against SARS-CoV-2 may modify some of these responses compared to natural infections. In this setting, it was felt necessary to also explore if early, innate immunity in human milk can protect against SARS-CoV-2. To explore this hypothesis, I reviewed the pathogenic mechanisms of Covid-19 focusing on the methods of viral entry through the human mucosae, infection establishment, immune dysregulation and disease causation and integrated these with the early actions by human milk feeding on mucosal infections. I then extrapolated the relevant pathways of human milk immune protection as potentials to protect against SARS-CoV-2. **Methods** This was divided into three steps which firstly included a literature search, secondly a step wise analyses and synthesis of data, and thirdly, an integration of data to form a hypothesis. The first step searched articles in two areas which in the first area, included articles on the infection and pathogenesis of SARS-CoV-2 and in the second area, included articles on innate immunity in human milk. In the second step, I analysed the immunological actions in human milk against mucosal infections, on the whole, and synthesised some of these relevant actions against the pathogenesis of SARS-CoV-2 infections. In the third step, I integrated human milk immune pathways that could interfere with the establishment of SARS-CoV-2 infection, viral invasion, immune dysregulation and the progression of the disease **Results** Infection by SARS-CoV-2 can theoretically be reduced or mitigated by the effect of early immune constituents in human milk. Human milk feeding may confer protection against all stages of the disease including establishment of SARS-CoV-2 infection, invasion and immune dysregulation and these actions may benefit both the individual and the community **Limitations** The multifunctional and dynamic nature in which human milk constituents function in a nursing infant cannot be fully reproduced by studying isolated components under experimental conditions. Even when such factors can theoretically offer protection against the virus, this concept has to be further researched in large cohorts of nursing infants. **Conclusion** The role of human milk in preventing the infection must be explored further and if true, exclusive human milk feeding must be considered as a reason for the smaller number of infections observed in children compared to adults in the pandemic. The additional counselling of human milk feeding for protection against novel pathogens, besides its established role in reducing neonatal mortality, would enhance rates of exclusive human milk feeding. General health can be developed and promoted through the potential immunotherapy provided by exclusive human milk feeding.

23 *Keywords:*

24 *human milk feeding, immunity, SARS-CoV-2, mucosal, immunotherapy*

25  
26  
27  
28  
29 **INTRODUCTION**

30

31 The pathogenesis of Covid-19 explains its clinical manifestations and highlights the importance of  
32 timely preventive therapy to prevent the infection or to reduce its impact.

33 Covid-19 is primarily a mild disease of childhood but its pathogenesis can involve multiple organ  
34 systems, especially the respiratory system. Its peak infectivity coincides with maximum SARS-CoV-2  
35 load, just before or within the initial five days of symptom onset [1]. The acute disease spectrum  
36 includes acute asymptomatic, mild and severe disease. Amongst children who develop severe  
37 disease, there are often predisposing factors such as obesity and bronchial asthma and other  
38 immunosuppressive conditions. There is a growing body of evidence that the virus is also temporally  
39 related to a post infective phenomena causing a novel disease now recognized to be a separate  
40 disease entity referred to as the Pediatric Multisystem Inflammatory disease which is temporally  
41 associated with Covid-19. Its manifestations are often acute, severe abdominal pain or high grade,  
42 often unremitting fevers refractory to antibiotics[1] Systemic impact can affect almost any system with  
43 the gastrointestinal, cardiac ,dermatological, renal, respiratory, haematological, or neurological  
44 systems involved by the disease [1].

45 Covid-19 may also impact long term health but while some children with Covid-19 continue to  
46 experience prolonged illness, most recover by day 56 of illness [2] .The spectrum of psychological  
47 impact of Covid-19 in children is well supported [3]

48 Children have a different susceptibility to the illness compared to adults [1] and this is attributed due  
49 to a number of factors[4]. Lower exposures to SARS-CoV-2 and differences in innate and adaptive  
50 immune responses in children may explain this. The presence of cross reactivity from other  
51 coronavirus infections due to previous exposures in children who have a greater frequency of upper  
52 respiratory infections may explain this. The differences noted in intestinal microbial colonization in  
53 children with a less inflammatory immune profile in the gut or the presence of higher blood levels of  
54 some factors such as melatonin have been suggested. Moreover, nonspecific, off target protection  
55 from live vaccination[4] may work independently or along with other factors to explain this difference.

56 Additionally, this article considers the possibility that the immunological benefits of human milk may  
57 also be a mechanistic explanation for the differences observed in children in this mucosal infection.

58 Human milk feeding allows every mother to provide immune defenses innately present in her milk,  
59 even without infection exposure. This can systematically hinder invasion of mucosal portals, prime  
60 targets of the SARS-CoV-2, and provide a number of antiviral defences, protecting from early  
61 infections. At the same time, the adaptive immunity in human milk which develops after exposure to  
62 infection mainly by antibody formation, is 'stimulated' or bridged by powerful innate immune factors.  
63 Maternal vaccination against the infection may further sustain and modify useful mucosal protective  
64 immune potentials.

65 It is noted that human milk does not transmit the SARS-CoV-2 to the nursing infant, instead, infected  
66 mothers produce specific antibodies in the milk [5], which are likely to protect. While SARS-CoV-2  
67 ribonucleic acid (RNA) was detected on several breast swabs it was not found in any breastmilk  
68 sample in women diagnosed with Covid-19. Moreover, SARS-CoV-2-specific antibodies of the  
69 immunoglobulin A (IgA) and immunoglobulin G (IgG) type were found correlating with SARS-CoV-2  
70 neutralization activity [5]. Of added importance is that the vaccination of breastfeeding women against  
71 SARS-CoV-2 produced specific IgA and IgG antibodies in breast milk for 6 weeks after vaccination.  
72 IgA was detected 2 weeks after vaccination followed by a spike in IgG after 4 weeks coinciding with a  
73 week after the second given vaccine [6].

74 To prevent subsequent pathogenesis of Covid-19 which is multi-fold but fuelled by a proinflammatory  
75 cytokine response, human milk can potentially modulate this by its predominant antiinflammatory

76 content and this has the potential to have impact on acute disease, tissue preservation and some of  
77 its sequelae.

## 78 79 2. MATERIAL AND METHODS 80

81 The review was divided into three steps which included:


- 82 1) literature search comprising two areas of interest
- 83 2) step wise analyses and synthesis of data
- 84 3) exploring the domain of overlap by integration and extrapolation

85 In the first step, articles searched were in two areas of interest. The first area included articles which  
86 focused mainly but not exclusively on the pathogenesis of SARS-CoV-2, coronaviruses, and other  
87 comparable infective agents. The second area of interest were articles which reviewed the innate  
88 immunological protection in human milk and its role against relevant mucosal diseases

89 In the search of the first area of interest, articles included were clinical research articles, experimental  
90 work, expert and interim guides. Publications selected included case reports, meta-analyses,  
91 systematic reviews on human infections by coronaviruses and other mucosal pathogens with  
92 comparable pathogenicity. Articles describing the pathogenesis of SARS-CoV-2 and its impact in the  
93 pandemic were reviewed. How mucosal viruses gain entry into the human body, establish and infect  
94 and go on to produce invasive disease and complications were explored. Articles that were excluded  
95 were Webpages which provide the public with questions and answers and media releases. Except for  
96 diabetes mellitus which was considered to significantly influence the unborn infant, specific underlying  
97 chronic conditions which could influence the pathogenesis of Covid-19 were excluded. The  
98 pathogenetic mechanisms of SARS-CoV-2 on geriatric patients were excluded. Specific social habits  
99 or dietary factors other than the influence by human milk feeding were excluded.

100 In the search of the second area of interest, articles included searches on breastfeeding and innate  
101 immunity and breastmilk immunology related to mucosal infections and SARS-CoV-2. Publications in  
102 this section included case reports, meta-analyses, systematic reviews, clinical research articles,  
103 reviews, and experimental work on humans and animals. The articles included reviewed the impact of  
104 innate immunity in human milk on infections and focused on those that involve the mucosal systems  
105 of the respiratory and gastrointestinal tract. Articles which elucidated how human milk factors prevent  
106 establishment of mucosal infections, can prevent mucosal invasion and modulate immune processes  
107 were reviewed. Except for a few articles that dealt with immunoglobulins in colostrum and human milk  
108 article which were included, articles that only dealt with adaptive immunity in breastmilk or on other  
109 aspects of breastmilk protection that was thought not to be directly relevant to the pathogenesis of  
110 mucosal infections were excluded.

111 Figure 1: Literature search areas



112  
113  
114 In the second step on data analyses and synthesis, the following methods were used:


115 Information from the pathogenesis of Covid-19 and innate breastmilk immune protection was  
116 analysed in three steps.

117 The first step was to explore how mucosal infections in general, and the SARS-CoV-2, specifically,  
118 infect mucosae to establish disease.

119 The second step analysed actions of breastmilk on immunity against various mucosal pathogens that  
120 were considered comparable to the SARS-CoV-2. The similarities of such pathogens included, the  
121 mucosal portals of entry for disease causation, the systemic impact such as the organs affected,  
122 inflammatory responses stimulated by them, and the age of infection.

123 The third step synthesised some of these relevant actions against the pathogenesis of SARS-CoV-2  
124 infections

125 Fig 2: Step wise analysis and synthesis of data




126  
127 In the last step, the domain that overlapped between the pathogenesis of SARS-CoV-2 infection and  
128 the pathways in innate human milk actions against mucosal infection and immune dysregulation were  
129 integrated as a whole to form a hypothesis with practical importance.

130 Integration and extrapolation indicated that in theory, the pathogenicity of the disease could be  
131 reduced or halted in a systematic manner, by human milk feeding. Mucosal entry, receptor blockade,

immune modulation, innate immune recognition, immune cells and antiviral activity were protective pathways by human milk feeding against SARS-CoV-2

Fig 3: Hypothesis: Protective domains in human milk feeding against the pathogenesis of SARS-CoV-2



### 3 Results and discussion

#### 3.1 SARS-COV-2 pathogenicity

SARS-CoV-2 is a large, spherical **single-stranded** RNA virus. It is a mucosal pathogen and genetically similar to SARS-CoV, but with a higher reproductive rate ( $R_0$ ) [5]. There are four main structural proteins, the nucleocapsid protein that contains the viral genome and three envelope proteins of which the spike protein, attaches to host cells through a receptor binding domain [7]

If timely clearance of the virus at the respiratory mucosae does not occur, the virus attaches itself to target receptors which are also found in many organs with hazards of widespread disease. SARS-CoV-2 binds to **angiotensin-converting enzyme-2** (ACE-2) receptors and fusion with a protein on host cell surfaces internalises the virus [8]. The virus is viable for days on smooth surfaces such as stainless steel, plastic or glass and at lower temperatures and humidity [8,9]. Of note is that cellular receptors of coronaviruses belong to the same protein family, and cellular entry occurs through the co-expression of other host peptidases which activate the coronavirus spike proteins [8]. The transmembrane serine proteases cleave and activate the coronavirus spike proteins during cell entry [8]. Spike protein dismantling releases infective viral genome, and with proofreading mechanisms in this RNA virus, a lower mutation rate [9] in the early stages of the pandemic was quickly followed by the **occurrence** of many dangerous mutants [10]. Droplets and contact with nasal, oral or conjunctival mucosae propagate the virus [10,11].

Fever, myalgia, headache, respiratory symptoms and temporary anosmia with taste loss due to transient damage to olfactory cells may occur [11]. Intracellular viral replication releases infective virions which stimulate host's innate immune responses [7,11]. Viral recognition stimulates T lymphocytes and dendritic cells to the site of infection for early viral clearance. Host immunity is induced to produce inflammatory factors, macrophages, maturation of dendritic cells, and the synthesis of interferons (IFNs), all vital for eliminating the virus. Neutralising antibodies are produced in SARS-CoV-2, possibly useful, but their exact duration and impact are yet unclear. The viral load may also be a factor in recovery [7]. Immune suppression, viral evasion, high viral load and host variables influenced by underlying conditions may contribute to more severe disease with spread to the lower airway [7,12]. Pneumonic lung involvement is associated with inflammation, confirmed by pathological findings [1,4]. Some develop septic shock, multi-organ dysfunction [6] which are important complications and Guo et al found that specific cytokines and serum markers were significantly higher in diabetic patients predisposing them to the inflammatory storm [12], and extensive tissue destruction is linked to hyperferritinemia [13]

In acute severe SARS-CoV2 many children had underlying predisposing factors such as obesity, bronchial asthma, sickle cell anemia and immunosuppression [1]. The other complication associated with the SARS -COV2 is multi-system inflammatory syndrome in children (MIS-C) [1]. Support of an

173 immune phenomena in children who recovered from mild disease and who were relatively healthy.  
174 Clinical and laboratory observations suggest many hypotheses of the inflammatory state that occurs  
175 in the disease some 2-6 weeks following an acute illness or exposure to SARS-CoV-2. Immune  
176 dysregulation in the genesis of MIS-C resulting from an exaggerated hyperimmune response is  
177 supported by positive serology and negative PCR testing, while the antibody or T-cell recognition of  
178 self-antigens (molecular mimicry) leading to synthesis of autoantibodies and formation of circulating  
179 immune complexes have been proposed[14]. The role of genes in clinical expression is suggested by  
180 differences in disease incidence in the world [14].

### 181 3.1.1 Immunobiology in children against SARS-CoV-2

182 Natural immunobiological mechanisms of children against the SARS-CoV-2 are more favourable than  
183 in adults and at least partially explain the relatively fewer mortalities amongst children in this disease  
184 compared to adults. The protective mechanisms include reduced expression of receptors that the  
185 virus utilizes to enter target cells, the differences in innate and adaptive immunity in this age group  
186 compared to adults which contribute to different immune dynamics, protective against the  
187 pathogenesis of this virus. The differences in childhood immunity are suggested to also preserve the  
188 pulmonary endothelial barrier and prevent acute respiratory distress syndrome (ARDS) [14].

### 189 4. Importance of innate immunity in human milk

190 Early immune responses of innate immunity are critical to deter viral survival in the human \severe  
191 respiratory infections can occur with specific gene polymorphisms of innate immune responses [15]  
192 and such genetic polymorphisms can delay, diminish or exaggerate antiviral responses [16] resulting  
193 in severe , invasive disease. Adding to this challenge is that respiratory pathogens have evolved  
194 processes to suppress or evade these important innate responses.

195 Evolutionarily, human nutrition provides innate protection from novel infections and prevents tissue  
196 damage as a result of it [17]. The mammary glands extract substances from maternal blood or may  
197 actively synthesise constituents with direct or indirect immune capacity. These substances are  
198 present in its cellular content, in the milk fat globule membrane found in milk, in its growth factors and  
199 in encrypted peptides within bioactive components. Many milk factors seem to have evolved for  
200 multiple functions with capacity to adapt to the mother infant dyad [17,18,19]. This makes human  
201 milk, on the whole, not reproducible in its immune potential, cost effective, and uniquely responsive in  
202 biological potential.

203 Human milk is empowered, through its innate immunity to fortify primary mucosal sites where  
204 infective agents gain entry[18,19],an early defence that is mandatory in the young with relative  
205 immunodeficiency. The infected mother can protect, by early innate immune responses[18,19], and  
206 further this by priming adaptive immune protection.

207 At chief sites of major antigenic challenge in the respiratory and gastrointestinal tract, innate defences  
208 strengthen the infant's developing immunity and in some situations give added individual protection  
209 as its immune content varies from mother to mother or with feeding time, in colostrum, transitional  
210 milk and mature milk[18,19], for such dynamic immune-protective potentials. Colostrum is produced  
211 in the first five days after birth, and is rich in white blood cells, human milk oligosaccharides (HMOs),  
212 bioactive factors such as immunoglobulin A(IgA), lactoferrin, growth and colony stimulating factors  
213 and antioxidants. Following this, transitional milk is produced up to 2 weeks postpartum which  
214 contains decreasing amounts of protein and higher lactose, fat and water-soluble vitamins. Mature  
215 milk, with does not show variation with regards to its nutrient content after 6 weeks postpartum. There  
216 are also differences in the milk of mothers who deliver at term compared to preterm with preterm milk  
217 containing increased proteins and specific immune factors [18]

### 219 4.1 Enhancing physical and chemical barriers by mucosal protection

220 The ciliated pseudostratified columnar epithelium which line most of the respiratory tract has special  
221 functions as a barrier to pathogens and foreign antigens, preventing infections and tissue injury

222 [20].Goblet cells secrete mucous, and form a vital layer of vigorous innate defence through  
223 mucociliary clearance[21].

224 Mucociliary clearance at the airway epithelium is augmented by the formation of mucous gel , the  
225 glycosylated mucin glycoproteins, with multiple defensive roles and transmembrane mucins such as  
226 MUC1 and MUC 4 as innate defences[21,22,23].Underlying the mucosal epithelia are leukocytes  
227 which secrete antibodies, defensins and lysozyme , for early immune defences[22].These substances  
228 provide a dual protection , acting as a physical barrier and providing direct antimicrobial activity, with  
229 capacity to opsonize microbes and clear them[22] .

230 Inefficient mucociliary clearance or absence of sufficient mucin glycoproteins in the airway disrupts  
231 this early and vital defense. Viruses can develop methods that interfere with early defences as in  
232 SARS- CoV -2 infections resulting in cell fusion, epithelial destruction , cilium shrinkage and other  
233 pathological changes to the epithelium[24],weakening its defense.

234 In the infant energy **dependent** processes must be conserved for growth and development and  
235 human milk is an investment towards this as nutrition is enriched by early defence ingredients.

236 For instance, mucosal tissues **utilize** energy to produce mucins, and increase their energy  
237 requirements to produce the important early defensive shield by mucin glycoproteins to fight off  
238 infections [22].However human milk nutrition has defensive mucous enriching factors that augment  
239 the amount of mucous in the respiratory tract or that step up early immunity by coating epithelial  
240 surfaces with mucous that prevents viral entry [25], and an effective step for primary infection  
241 prevention. Mucins in human milk add on a layer to the developing immunity in the gastrointestinal  
242 and respiratory tracts by supporting the prevention of adhesion of pathogens to the cell surface [25].  
243 MUC1 and MUC4 competitively inhibit receptor to **viral** interaction [25].Sialyated human milk mucin  
244 inhibits viral binding to the infant's cell surface glycan receptor and inhibits rotavirus in the  
245 gastrointestinal tract, blocking experimental adhesion of recombinant norovirus-like particles, possibly  
246 emulated in action for immunotherapy[25,26]

247 Human milk proteins impact at **the** core of immune defences by stimulating gene expression.  $\beta$ -  
248 casein, for example, stimulates MUC2 gene expression for increased goblet cell numbers [27,28]  
249 Additionally mucous secretion is also enhanced by substances such as epidermal growth factor  
250 (EGF) increasing mucin production by goblet cells [28], enhancing synthesis and secretion of  
251 mucous.

252 Trefoil factors, are cellular products that produce mucin in breastmilk and step up immunity by  
253 activating intestinal epithelial cells and healing of mucosae [29], enhancing tissue repair and limiting  
254 tissue damage. Mucosal barriers remove the virus by agglutination and expulsion through muco-  
255 ciliary action in the respiratory tract or peristaltic movement in the gut [30].

256 Epithelial adherence and **colonization** prevent infection and complications but could also control  
257 infection transmission. Human milk oligosaccharides (HMOs), which are found abundantly in human  
258 milk, coat epithelial surfaces and prevent pathogen contact and adherence to epithelia, an important  
259 mechanism which would otherwise permit viral replication. Soluble fucosylated and sialyated HMOs  
260 are bound by lectin receptors of fucose or sialyl-dependent pathogens, entrapping viruses so the host  
261 innate immune system cannot **recognize** them. HMOs are also prebiotics for commensal microbes,  
262 along with other factors in human milk, augment holistic health and fortify epithelia to prevent early  
263 steps of infection such as viral adherence [31].

#### 264 **4.2 Receptor blockage**

265 Viral entry sabotages cellular machinery for viral replication. Blocking cellular entry by interrupting  
266 viral receptors, can prevent **cellular internalisation of virus**. The SARS-COV-2 requires specific ACE-2  
267 receptors [4] to enter cells while heparan sulfate proteoglycan (HSPG) receptors assist in SARS-  
268 COV-2 cell entry [32], establishing infection.

269 Human milk has ingredients that are “receptor decoys” in early infection prevention [31]. Viruses  
270 **utilize** cell surface glycoconjugates as receptors to enter cells, while some human milk  
271 oligosaccharides (HMOs), abundant in early nutrition, express glycans that bind onto host cell surface  
272 lectins and prevent viral binding and invasion[33]. Not all breastfeeding mothers can effectively  
273 provide protection through this route, as specific HMO glycosylation providing these receptors  
274 depends on factors such as the mother’s blood Lewis status[34].

275 The **antiviral** spectrum in **human milk** such as cytokines, monolaurin, Vitamin A, Tenascin C,  
276 **lactadherin, lactoferrin** and others and this may be captured even where **direct nursing is not**  
277 **feasible, through milk banks that collect milk with specific properties [35].**

278 **Lactoferrin is a multifunctional glycoprotein and is found abundantly in colostrum [35].** It fortifies  
279 human nutrition with antiviral action by direct and indirect methods. Its dynamic levels increase as  
280 lactation progresses to the second year [36], re-emphasising holistic importance of sustained  
281 breastfeeding. Lactoferrin acts against a gamut of non-enveloped and enveloped DNA and RNA  
282 viruses through numerous mechanisms; inhibiting cellular entry, by direct attachment to the virus or  
283 by blocking cellular receptors. Its action against human pathogens such as Herpes simplex virus,  
284 human papillomavirus, human immunodeficiency virus (HIV), and rotavirus from entering host cells, is  
285 notable at the step where these viruses enter cells utilising common cell surface receptors such as  
286 heparan sulfate glycosaminoglycan cell receptors (HSPG)[37].

287 SARS-CoV and SARS-CoV-2 are similar in their sequences and receptor-binding domain structure  
288 [38], hence they are compared when reviewing viral pathogenicity. **Lactoferrin protects against SARS-  
289 CoV infection by binding to HSPGs, interrupting the initial interaction between SARS-CoV and host  
290 cells[39].** Additionally, lactoferrin may also interrupt the step of cellular entry of SARS-CoV-2 which  
291 **also utilises HSPG as cofactor, for cell anchor and entry [32].**

292 The **antiviral** spectrum of lactoferrin includes fighting off infections that depend on iron. Lactoferrin  
293 interferes with iron **utilization** of pathogens. Viruses may also infect iron-acquiring cells by binding to  
294 another human milk protein, transferrin receptors during cell entry. Other viruses alter proteins  
295 involved in iron homeostasis. In coronavirus infection and inflammation, lactoferrin **plays** a preventive  
296 role in the respiratory and gastrointestinal tract [40].

297 **While the levels of the various immunoglobulin fractions differ in colostrum and milk, IgA is generally  
298 the main immunoglobulin, immunoglobulin M(IgM)the second most dominant immunoglobulin and  
299 immunoglobulin G(IgG)is the least dominant compared to the IgA and IgG[41] Secretory  
300 immunoglobulin A (SIgA), is the main antibody in mucosal secretions and may engage multiple  
301 innate mechanisms for early antiviral protection. It consists of two or more IgA monomers joined by a  
302 J chain in association with SC which helps transport and release IgA into the intestinal lumen. It also  
303 protects IgA from proteolysis and anchors IgA in the mucus layer overlying the mucosal surfaces [42]**

304 While SARS-CoV-2 SIgA responses in human milk follow maternal recovery from COVID-19[43], the  
305 protective mechanism by this tetrameric complex with secretory component (SC) primarily of mucosal  
306 adaptive immune functions in this scenario is not known. However, timely innate antimicrobial  
307 protection by SIgA at intestinal mucosal sites by blocking receptor binding, immune exclusion and  
308 interference with pathogen virulence determinants [42] has been demonstrated against other  
309 pathogens

310 A cohort study of lactating parents compared human milk mRNA vaccination responses to responses  
311 to Covid-19 infections .This study found differences in IgA and IgG antibodies in human milk between  
312 COVID-19 infection and mRNA vaccination and these differences were noted for up to 90 days.  
313 Infection was associated with a variable IgA-dominant response that was stable up to 90 days after  
314 diagnosis and vaccination was linked to an IgG-dominant response. The concentration of IgG  
315 response was noted to increase after each vaccine dose and to start to decline by 90 days after the  
316 second dose. There was increased human milk IgA only after the first dose following vaccination. Both  
317 infection and vaccination produced neutralization activity against live SARS-CoV-2 virus in human  
318 milk [44].

### 319 4.3 Innate immune recognition

320 Timely, selective and regulated pathogen recognition must differentiate from the plentiful commensals  
321 in the human body. Antiviral immune attack must also minimise destruction of normal tissue and  
322 commensal microbes. Cells infected with viruses must be destroyed early by focused immune  
323 recognition with effective and regulated antiviral responses. At the same time, where dysregulated  
324 immunity can cause invasive disease and tissue destruction, as in the immunopathology of invasive  
325 SARS- CoV-2 infection, the antiviral action of human milk along with its capacity for anti-inflammation  
326 and immunomodulation could be useful to counter or reduce this immunopathology.

327 The innate immune system recognizes pathogens by pathogen-recognition receptors (PRRs) that  
328 sense distinct pathogen-associated molecular patterns (PAMP). Toll-like receptors (TLR) are activated  
329 and signalled by RNA viruses through RNA sensors [45]. Members of the TLR family detect viruses  
330 and induce the production of interferons through several signalling proteins. Reproducing this, TLR  
331 agonists are suggested as therapy [45] The SARS-CoV-2 activates TLR2 signalling, which results in  
332 the robust expression of proinflammatory cytokines [46].

333 Human milk components can selectively recognize pathogens and differentiate them from  
334 commensals. TLR signalling is important for such differential and specific recognition [47,48]. In  
335 human milk there are specific TLR responses on different cellular components based on TLRs that  
336 are activated; such responses are not found in infant formulas [48]. TLR2, TLR3, TLR5 and soluble  
337 cluster of differentiation (sCD)14, and human  $\beta$ -defensin-1 (hBD-1), function as pattern recognition  
338 receptors for innate immune recognition[18] . PRRs in human milk and other bioactive substances in  
339 the intestine of the breastfed infant create an anti-inflammatory environment , while TLR responses  
340 can be modified by soluble toll-like receptors (sTLRs) and sCD14[18,48,49].

341 The immunomodulation in human milk potentially fine tunes specific TLR mediated inflammatory  
342 responses, while focusing on defences against viruses, interacting sTLRs and sCD14 with a  
343 spectrum of bioactive factors.

344 When the impact of human milk is integrated with the pathogenesis of the disease in the  
345 gastrointestinal tract which is an important organ in Covid-19 pathogenesis in children, the benefits of  
346 human milk feeding on the intestinal microbiome adds on to the spectrum of innate defences.  
347 Lactoferrin, is one of a spectrum of substances in human milk , which can promote the gut milieu. It  
348 enhances the growth of enterocytes and along with anti-inflammatory and immunomodulatory actions,  
349 steps up mucosal immunity at the gut epithelial barrier [38].

### 350 4.4 Immune cells

351 Immune cells and their antiviral products prevent or limit the infection.

352 Maternal blood leukocytes that home to the mammary gland travel through epithelial cell spaces to be  
353 secreted into milk, whereas blood monocytes reaching the mammary gland become activated and

354 function as motile macrophages, secreted into breastmilk for various dynamic immune functions  
355 [18,19, 50,51]. Immune constituents are also guided into mother's milk by mucosal immunity as the  
356 lactating mammary gland and its products are integral to this immune compartment [18,19]. Holistic  
357 maternal health including the health of the mother's lactating mammary glands may be important for  
358 this.

359 Human milk immune cells include epithelial cells, the motile macrophage, neutrophils, lymphocytes,  
360 innate lymphoid cells (ILCs), hematopoietic progenitor cells and stem cells.[51,52] There are epithelial  
361 cells, macrophages (32.6%) , neutrophils (45.1%) and lymphocytes (21.3%), characterized mainly by  
362 CD3+ T cells (83%), distributed between CD4+ and CD8+[52, 53] , as well as Tγδ+ cells (11%),  
363 CD16+ NK cells (3-4%), and B cells (2%).[52, 54] While some immune cells transferred in milk last in  
364 the infant for about 6 days [51,55], human milk can continue to stimulate the proliferation and survival  
365 of milk neutrophils and macrophages through colony stimulating factors (CSF)[52].In the mother who  
366 expresses milk, milk cells remain viable for a few hours after expression , and do not typically survive  
367 after freezing or pasteurization[52], stressing advantages of direct human milk feeding.

368 Individual protection is evident in the milk of mothers whose infants have severe bronchiolitis where  
369 there are an increased number of live cells .Milk from mothers of infants who were hospitalized with  
370 bronchiolitis had increased viable cells compared to milk from mothers of healthy infants (1.3±0.4 vs.  
371 0.3±0.03×10(6) cells/ml, mean±s.e.m.p≤0.001).Maternal milk cells from infants hospitalized with  
372 bronchiolitis produced a skewed cytokine profile *ex vivo* in response to stimulation by live respiratory  
373 syncytial virus but not when cultured with a non-specific mitogen [56]

374 Animal experiments indicate that pluripotent stem cells in human milk can replicate and differentiate  
375 outside the mammary cell lineage and can integrate into distant organs [57]. For instance, it is  
376 fascinating that human milk stem cells can reach the brain and differentiate into neurons and glial  
377 cells [54], and it is hypothesised that such cells can repair damaged or injured tissue in the aftermath  
378 of invasive viral infections.

#### 379 4.5 Immune modulation

380 Human milk augments immune maturity and modulates immunity in the developing immune system.  
381 While there is still a lot more about immune modulation in human milk to be known, it is a dynamic  
382 process that seems to respond to the infant's needs.

383 Lactoferrin,as mentioned above, is a human milk constituent with multiple antiviral actions. It also  
384 binds viruses, blocks some viruses from attaching to target cells and can suppress intracellular viral  
385 replication. Lactoferrin receptors are found in many immune cells such as monocytes and  
386 lymphocytes. Lactoferrin activates antigen presenting cells (APC) and can link innate and adaptive  
387 immune functions for T and B cells. The anti-inflammatory action of lactoferrin on leukocytes that are  
388 stimulated with lipopolysaccharides (LPS) is associated signalling proteins[58]

389 Experimentally, infected bronchial cells are protected from inflammation and cell necrosis by  
390 lactoferrin [59]. Lactoferrin is an iron scavenger and modulates signalling pathways. It helps reduce  
391 the production of pro-inflammatory cytokines and reactive oxygen species (ROS)[59].

392 When these are extrapolated to the nursing infant, lactoferrin, in human milk, may similarly reduce  
393 immune dysregulation in the 'cytokine storm' recognised as a complication of SARS-CoV-2, through  
394 anti-inflammatory impact, and by this, could reduce lung damage in the infection.

395 In the gastrointestinal tract, lactoferrin transports iron and deprives iron from iron-dependent  
396 microbes, reducing their infectivity. Through its action on iron, lactoferrin may have a role in the

397 hyperferrinemia associated with Covid -19. Preventing thrombocytopenia, through platelet surface  
398 receptors may help in the hypercoagulable state, recognised in COVID-19[59] Lactoferrin and other  
399 substances stimulate effective immune responses by recruiting APCs to enhance adaptive  
400 immunity[58,59].

401 Responsive immune-protection is evident during active infections. In nursing infants, mother's milk  
402 showed increased total number of white blood cells, especially macrophages, and TNF $\alpha$  levels [50], a  
403 regulation that could accelerate recovery in the nursing infant. Individual protection through human  
404 milk occurs within the dynamics of a unique compartment distinct from maternal plasma,  
405 predominantly anti- inflammatory, differing among mammalian species, influenced by diet and stage  
406 of feeding, with notable differences in colostrum and mature milk [19,60].

407 At the, the microscale, human milk is also dynamically regulated. Human milk microribonucleic acids  
408 (miRNAs) are mainly produced in the mammary gland, while small amounts are drawn from maternal  
409 blood with lactation-specific regulatory functions. Cells, exosomes and fat globules protect milk  
410 miRNA and transfer them to the infant's bloodstream [60]. A study found that while the total miRNA  
411 provided to the nursing infant is constant in the first six months of lactation, the miRNA concentrations  
412 are altered in the fourth month compared to the second and sixth month. The authors suggest that  
413 this may be due to remodelling of the mammary gland in response to the infant's changing feeding  
414 patterns, as an adaptation to the infant's needs [60]

415 Additionally, maternal diet can transfer into human milk subtypes of miRNAs codified by non-human  
416 genomes but still present in the circulation [61], and some have been noted to have antiviral immune  
417 activity such as the freely circulating xeno-miRNA (XenomiRs), against the Influenza A viruses  
418 (IAVs)[62].

419 Immunomodulatory activity in human milk is supported by some reduction to allergies and immune -  
420 related diseases in later life in the breastfed. A fortified mucosal layer induced by human milk  
421 microbes, sIgA, cytokines and immunomodulatory substances prevents microbial translocation across  
422 mucosal surfaces [63]. This may be important to prevent overstimulation of systemic immunity.  
423 Through exclusive human milk feeds, the establishment of a "mother-microbe-infant-microbe" link  
424 renders human milk as helpful against acute diseases and protective for long term health [64,65].

426 The framework of disease prevention by human milk feeding can be compared to the basic principles  
427 of vaccinology [66]. Human milk is an excellent vaccine as it has an incomparable safety profile and  
428 can prevent clinical infection. By preventing mucosal pathogens from gaining entry into the body by  
429 protecting against epithelial colonization, innate immunity can also decrease person-to- person and  
430 community transmission of the virus.

431 Through timely prevention, human milk antiviral factors potentially reduce the infective load which  
432 naturally prevents severe infection and its consequences.

433 Hence, human milk can act as primary and secondary prevention in such infections.

435

436

437

438

439

440


441

442

**Fig 4: Possible defenses by lactoferrin in human milk against SARS-CoV-2**

443

444



445

## 5. Conclusion

446

447

448

449

450

451

452

It is of interest that the integration of the pathogenesis of Covid-19 with the immunological actions of human milk feeding, supports a theoretical possibility for stepwise protection in human milk against the virus. While innate immune protection in human milk potentially protects the mucosae, against viral entry, viral invasion and disease complications, studies indicate that human milk responses may be modified by maternal vaccination in SARS-CoV-2 infections. This may be a strategy that could enhance human milk anti SARS-CoV-2 immunoprotection..

453

While much research in this area is needed, it is important to continue to emphasize exclusive human milk feeding as an important modifiable variable that promotes infection protection and holistic health.

454

455

## COMPETING INTERESTS

456

There are no competing interests

457

458

## AUTHOR'S CONTRIBUTION

459

460

461

The single author as named above formed the idea of the review, designed the review, did the literature search, reviewed the relevant papers, analysed , synthesised and integrated the information , wrote the first and final draft of the manuscript , then read and approved the final manuscript

462

463

## CONSENT

464

Not applicable

465

466

## CONFLICT OF INTEREST

467

468

All work is referenced correctly to the best of my knowledge.

469

The author declares no ethical issues or conflict of interest after the work is published

470

471

472

## REFERENCES

473

474

475

476

477

478

479

480

481

482

- 1.Rubens JH, Akindede NP, Tschudy MM Acute Covid 19 and multisystem inflammatory syndrome in children BMJ 2021;372: n385
- 2.Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al Lancet Child Adolesc Health 2021; S2352-4642(21)00198-X
- 3.Chawla N, Tom A , Sen MS , Sagar R Psychological Impact of COVID-19 on Children and Adolescents: A Systematic Indian J Psychol Med. 2021; 43(4): 294–299.

- 483 4.Zimmermann P, Curtis N Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying  
484 the age-related difference in severity of SARS-CoV-2 infections Arch Dis Child 2020; archdischild-2020-320338.  
485  
486  
487 5.Pace RM, Williams JE, Järvinen KM, Belfort MB, Pace CDW, Lackey KA, et al COVID-19 and human milk: SARS-CoV-  
488 2, antibodies, and neutralizing capacity Version 1. medRxiv. Preprint. 2020 Sep 1  
489  
490  
491 6.Perl SH, Yulzari AU, Klainer H, Asiskovich L, Youngster M, Rinott E, Youngster I. SARS-CoV-2-Specific Antibodies in  
492 Breast Milk After COVID-19 Vaccination of Breastfeeding Women JAMA 2021 ;325 :19  
493  
494 7.Hosseini A, Hashemi V, Shomali N, Asghari F. Gharibi T, Akbari M, Gholizadeh S, Jafarif A  
495 Innate and adaptive immune responses against coronavirus Biomed Pharmacother. 2020; 132: 110859  
496  
497 8.Cevik M, Kuppalli K, Kindrachuk J, Peiris M Virology, transmission, and pathogenesis of SARS-CoV-2 371 BMJ  
498 2020;371:m3862  
499  
500 9.Bakhshandeh B, Jahanafrooz Z, Abbasi A, Goli MB, Sadeghi M, Mottaqi MS, Zamani M Mutations in SARS-CoV-2;  
501 Consequences in structure, function, and pathogenicity of the virus Microb Pathog 2021 ;154:104831.  
502  
503 10.Lubbe W, Botha E, Vilen HN , Reimer P Breastfeeding during the COVID-19 pandemic – a literature review for clinical  
504 practice International Breastfeeding Journal 2020; 15:82  
505  
506 11.Gori A, Leone F, Loffredo L, Cinicola BL, Brindisi G , De Castro G et al COVID-19-Related Anosmia: The Olfactory  
507 Pathway 2020 Front Neurol. 2020; 11: 956.  
508  
509 12.Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C Diabetes is a risk factor for the progression and prognosis of  
510 COVID-19 Diabetes Metab Res Rev 2020; e3319  
511  
512 13.Kappert K, Jahić A, Rudolf Tauber R Assessment of serum ferritin as a biomarker in COVID-19: bystander or  
513 participant? Insights by comparison with other infectious and non-infectious diseases Biomarkers 2020; 8:616-625  
514  
515 14. Shankaralingappa A, Thirunavukkarasu AB. Pathogenesis of COVID-19 and multi-system inflammatory syndrome in  
516 children. Int J Contemp Pediatr. 2021 ;8(4):777-781  
517  
518 15.Melendi GA, Coviello S, Bhat N, Hernandez JZ, Ferolla FM, Polack FP Breastfeeding is associated with the production  
519 of type I interferon in infants infected with influenza virus Acta Paediatr 2010 ;99(10):1517-21  
520  
521 16.Kikkert M Innate Immune Evasion by Human Respiratory RNA Viruses Review J Innate Immun 2020;12(1):4-20.  
522  
523 17.Vorbach C, Capecchi MR, Penninge JM Evolution of the mammary gland from the innate immune system? BioEssays  
524 2006; 28(6):606-16  
525  
526 18.Cacho NT, Lawrence RM Innate Immunity and Breast Milk Front Immunol 2017; 29:8:584  
527  
528 19.Ballard O, Morrow AL, Human Milk Composition: Nutrients and Bioactive Factor Pediatr Clin North Am. 2013 :60(1);  
529 49–74.  
530  
531 20.Kia'i N, Bajaj T. Histology, Respiratory Epithelium. [Updated 2021 May 10]. In: StatPearls [Internet]. Treasure Island  
532 (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK541061/>  
533  
534  
535 21.Chatterjee M, van Putten JPM, Strijbis K. Defensive properties of mucin glycoproteins during respiratory infections—  
536 relevance for SARS-CoV-2. mBio 2020; 11: e 02374-20.  
537  
538 22.Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA Mucins in the mucosal barrier to infection Mucosal  
539 Immunol. 2008; 1(3): 183–197  
540  
541 23.Mthembu Y, Lotz Z, Tyler M, de Beer C, Rodrigues J, Schoeman L, et al Mall Purified human breast milk MUC1 and  
542 MUC4 inhibit human immunodeficiency virus Neonatology 2014;105(3);211-7.  
543

- 544 24.Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F et al. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in  
545 human airway epithelial cells. *Nat Commun* 2020; 11: 3910  
546
- 547 25.Turin CG, Ochoa TJ The Role of Maternal Breast Milk in Preventing Infantile Diarrhea in the Developing World *Curr*  
548 *Trop Med Rep.* 2014; 1(2): 97–105  
549
- 550 26.Peterson R, Cheah WY, Grinyer J, Packer N Glycoconjugates in human milk: protecting infants from disease.  
551 *Glycobiology.* 2013; 23(12):1425-38.  
552
- 553 27.Jakaitis B M, Denning PW Human Breast Milk and the Gastrointestinal Innate Immune System *Clin Perinatol.* 2014;  
554 41(2): 423–435.  
555
- 556 28.Dvorak B Milk Epidermal Growth Factor and Gut Protection *J Pediatr.* 2010 ;156(2 Suppl): S31–S35  
557
- 558 29.Barrera GJ, Sanchez G, Gonzalez JE Trefoil factor 3 isolated from human breast milk downregulates cytokines (IL8  
559 and IL6) and promotes human beta defensin (hBD2 and hBD4) expression in intestinal epithelial cells HT-29 *Bosn J Basic*  
560 *Med Sci.* 2012; 12(4): 256–264.  
561
- 562 30.Mantis NJ, Rol N, Corthésy B Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut *Mucosal*  
563 *Immunol.* 2011;4(6):603–611.  
564
- 565 31.Wiciński M, Sawicka E, Gębalski J, Kubiak K, Malinowski B Human Milk Oligosaccharides: Health Benefits, Potential  
566 Applications in Infant Formulas, and Pharmacology *Nutrients* 2020;12(1):266  
567
- 568 32.Zhang Q, Chen CZ, Swaroop M, Xu M, Wang L, Lee J, et al Heparan sulfate assists SARS-CoV-2 in cell entry and can  
569 be targeted by approved drugs in vitro *Cell Discov* 2020;6(1):80  
570
- 571 33.Etzold S, Bode L Glycan-dependent viral infection in infants and the role of human milk oligosaccharides. *Curr. Opin.*  
572 *Viro.* 2014;7; 101–107.  
573
- 574 34.Yang B Protection from Viral Infections by Human Milk Oligosaccharides: Direct Blockade and Indirect Modulation of  
575 Intestinal Ecology and Immune Reactions *Open Glycoscience* 2012;5(1);19-25  
576
- 577 35.Wedekind SIS, Shenker NS Antiviral Properties of Human Milk Microorganisms. 2021; 9(4): 715.  
578
- 579 36.Perrin MT, Fogleman AD, Newburg DS, Allen JC longitudinal study of human milk composition in the second year  
580 postpartum: implications for human milk banking. *Matern Child Nutr.* 2017;13(1): e12239  
581
- 582 37.Redwan EM, Uversky VN, El-Fakharany EM, Al-Mehdar H Potential lactoferrin activity against pathogenic viruses *C R*  
583 *Biol* 2014 ;337(10):581-95  
584
- 585 38. Peroni DG, Fanos V Lactoferrin is an important factor when breastfeeding and COVID-19 are considered *Acta*  
586 *Paediatr.* 2020: 109(10):2139-2140.  
587
- 588 39. Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G et al Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin  
589 Binding to Heparan Sulfate Proteoglycans *PLoS One.* 2011; 6(8): e23710.  
590
- 591 40.Wang Y, Wang P, Wang H, Luo Y, Wan L, Jiang M , et al Lactoferrin for the treatment of COVID- 19 (Review) *Exp*  
592 *Ther Med.* 2020 ; 20(6): 272  
593
- 594 41.El-Loly MM, Guirguis AH, Abdel-Ghany AS Antibodies of Human Milk within the First Week of Birth *RRJFPDT* 2018;6  
595 :1  
596
- 597 42. Mantis NJ, Forbes SJ Secretory IgA: Arresting Microbial Pathogens at Epithelial Borders *Immunol Invest.* 2010; 39(0):  
598 383–406.  
599
- 600 43. Fox A , Marino J, Amanat F, Krammer F, Holbrook JH , Pazner SZ et al Evidence of a significant secretory-IgA-  
601 dominant SARS-CoV-2 immune response in human milk following recovery from COVID-19 Paper in collection COVID-19  
602 SARSCoV-2preprints from medRxiv and bioRxiv medRxiv 2020.05.04.20089995; doi:  
603 <https://doi.org/10.1101/2020.05.04.20089995>  
604

605 44.Young BE, Seppo AE, Diaz N, Rosen-Carole C, Nowak-Wegrzyn A, Cruz Vasquez JM, et al Association of Human  
606 Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination. *J*  
607 *Pediatr* 2021 Nov 10: e214897. doi: 10.1001/jamapediatrics.2021.4897. Epub ahead of print. PMID: 34757387; PMCID:  
608 PMC8581794.

609 45.Xagorari A, Chlichlia K Toll-Like Receptors and Viruses: Induction of Innate Antiviral Immune Responses *Open*  
610 *Microbiol J.* 2008; 2: 49–59.

611 46.Sariol A, Stanley Perlman S. SARS-CoV-2 takes its Toll *Nat. Immunol* 2021 ;22: 801–802

612 47.He YY, Lawlor NT, Newburg DS Human Milk Components Modulate Toll-Like Receptor–Mediated Inflammation *Adv*  
613 *Nutr.*2016; 7(1): 102–111.

614 48.LeBouder E, Rey-Nores JE, Raby AC, Affolter M, Vidal K, Thornton CA, Labéta MO Modulation of neonatal microbial  
615 recognition: TLR-mediated innate immune responses are specifically and differentially modulated by human milk. *J*  
616 *Immunol.* 2006; 176(6):3742-52.

617 49. Chatterton DE, Nguyen DN, Bering SB, Sangild PT Anti-inflammatory mechanisms of bioactive milk proteins in the  
618 intestine of newborns. *Int J Biochem Cell Biol.* 2013; 45(8):1730-47.

619 50.Riskin A, Almog M, Peri R , Halasz K , Srugo I, Kessel A Changes in immunomodulatory constituents of human milk in  
620 response to active infection in the nursing infant *Pediatric Research* 2012 : 71: 220–22

621 51.Baban B, Malik A, Bhatia J, Yu JC Presence and Profile of Innate Lymphoid Cells in Human Breast Milk *JAMA*  
622 *Pediatr.* 2018; 172(6): 594–596.

623 52.Palmeira P, Sampaio MC Immunology of breast milk *Rev. Assoc. Med. Bras.* 2016; 62: 6

624 53. Barros MD, Carneiro-Sampaio MMS. Milk composition of low birth weight infant mothers. *Acta Paediatr Scand.* 1984;  
625 73:693-5.

626 54. Lepage P, Van de Perre P. The immune system of breast milk: antimicrobial and anti-inflammatory properties. *Adv*  
627 *Exp Med Biol.* 2012; 743:121-37.

628 55. Cabinian A, Sinsimer D, Tang M, Zumba O, Mehta H, Toma A et al Transfer of Maternal Immune Cells by  
629 Breastfeeding: Maternal Cytotoxic T Lymphocytes Present in Breast Milk Localize in the Peyer's Patches of the Nursed  
630 Infant. *PLoS One.* 2016; 11(6):e0156762.

631 56. Bryan DL, Hart PH, Forsyth KD, Gibson RA Immunomodulatory constituents of human milk change in response to  
632 infant bronchiolitis. *Pediatr Allergy Immunol.* 2007; 18(6):495-502.

633 57.Aydın MS, Yiğit EN , Vatandaşlar E, Erdoğan E, Öztürk G Transfer and Integration of Breast Milk Stem Cells to the  
634 Brain of Suckling Pups *Scientific Reports* 2018; 8 : 14289

635 58.Actor JK, Hwang SA, Kruzel ML Lactoferrin as a Natural Immune Modulator *Curr Pharm Des.* 2009; 15(17): 1956–197

636 59. Habib HM, Ibrahim S, Zaim A, Ibrahim WH The role of iron in the pathogenesis of COVID-19 and possible treatment  
637 with lactoferrin and other iron chelators *Biomed Pharmacother* 2021; (13) 136:111228

638 60.Alsaweed M, Lai CT, Hartmann PE, Geddes DT, Kakulas F Human Milk Cells and Lipids Conserve Numerous Known  
639 and Novel miRNAs, Some of Which Are Differentially Expressed during Lactation. *PLoS One.* 2016; 11(4): e0152610.

640 61.Stephen BJ, Pareek N, Saeed M, Kausar MA, Rahman S, Datta M *Front. Immunol.*, Xeno-miRNA in Maternal-Infant  
641 Immune Crosstalk: An Aid to Disease Alleviation *Front Immunol.* 2020; 11: 59.

642 62.Zhou Z, Li X, Liu J, Dong L, Chen Q, Liu J, et al Honeysuckle-encoded atypical microRNA2911 directly targets  
643 influenza A viruses. *Cell Res.* 2015; 25(1):39-49.

662

663 63.Harmancıoğlu B, Kabaran S Breast Milk: Its Role in Early Development of the Immune System and Long-Term Health  
664 2019 OJOG 9(04):458-473

665 64.Hogenová H T, Kverka M, Hrdý J.b Immunomodulatory Components of Human Colostrum and Milk Ogra PL, Walker  
666 WA, Lönnnerdal B (eds): Milk, Mucosal Immunity and the Microbiome: Impact on the Neonate. Nestlé Nutr Inst Workshop  
667 Ser. Basel, Karger 2020; 94 :38–47

668 65.Kutty PK “Mother-Microbe-Infant-Microbe” Synchrony– A Mini Review JAMMR 2020 ;32: 24

669 66.Pollard AJ, Bijker EM A guide to vaccinology: from basic principles to new developments Nature Reviews Immunology  
670 2021; 21: 83–100